ULTANE Drug Patent Profile

When do Ultane patents expire, and when can generic versions of Ultane launch?

Ultane is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in ULTANE is sevoflurane. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ultane

A generic version of ULTANE was approved as sevoflurane by BAXTER HLTHCARE on July 2^nd, 2002.

Summary for ULTANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	16
Patent Applications:	1,959
Drug Prices:	Drug price information for ULTANE
What excipients (inactive ingredients) are in ULTANE?	ULTANE excipients list
DailyMed Link:	ULTANE at DailyMed

See drug prices for ULTANE

Recent Clinical Trials for ULTANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Keith M. Vogt, MD, PhD	Phase 1
National Institute of General Medical Sciences (NIGMS)	Phase 1
Alberta Children's Hospital	Phase 2

See all ULTANE clinical trials

Pharmacology for ULTANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

US Patents and Regulatory Information for ULTANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995	AN	RX	Yes	Yes

Expired US Patents for ULTANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995

EU/EMA Drug Approvals for ULTANE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Zoetis Belgium SA	SevoFlo	sevoflurane	EMEA/V/C/000072 For the induction and maintenance of anaesthesia in dogs and cats.	Authorised	no	no	no	2002-12-11
Chanelle Pharmaceuticals Manufacturing Limited	Sevohale (previously known as Sevocalm)	sevoflurane	EMEA/V/C/004199 For the induction and maintenance of anaesthesia.	Authorised	yes	no	no	2016-06-21

International Patents for ULTANE

See the table below for patents covering ULTANE around the world.

Country	Patent Number	Title	Estimated Expiration
China	1152674
Colombia	4920220	COMPOSICIONES QUE CONTIENEN COMPUESTOS FLUOROETER Y METODOS PARA INHIBIR SU DEGRADACION EN PRESENCIA DE UN ACIDO DE LEWIS
New Zealand	504866	Container for an inhalation anesthetic having at least an internal surface that is inert and impermeable to the inhalation anesthetic
Slovenia	1045686
Spain	2170474

Ultane: Understanding the Market Dynamics and Financial Trajectory

Introduction to Ultane

Ultane, also known as sevoflurane, is a widely used inhalation anesthetic. It is part of the broader category of general anesthesia drugs, which are crucial in various medical procedures. To understand the market dynamics and financial trajectory of Ultane, it is essential to delve into the broader context of the general anesthesia drugs market and the specific segment of inhalation anesthetics.

Global General Anesthesia Drugs Market

The global general anesthesia drugs market is projected to grow steadily over the coming years. Here are some key points:

• Market Size and Growth: The global general anesthesia drugs market was valued at USD 4,978.1 million in 2023 and is expected to reach USD 6,898.4 million by 2033, growing at a CAGR of 3.3% during this period[3].

Inhalation Anesthetics Market

Inhalation anesthetics, including Ultane, form a significant segment within the general anesthesia drugs market.

Market Size and Growth

• The inhalation anesthetics market is estimated to reach USD 1.38 billion in 2024 and is expected to grow to USD 1.74 billion by 2029, with a CAGR of 4.57% during the forecast period[4].

Key Drivers

• The application of inhalation anesthetics in the diagnosis and treatment of COVID-19 and associated diseases has positively impacted the market's growth. Volatile agents like sevoflurane are effective in patients requiring complex and high sedation, reducing the need for intravenous sedatives[4].

Regional Growth

• The Asia Pacific region is expected to grow at the highest CAGR over the forecast period, driven by increasing healthcare infrastructure and demand for advanced medical services[4].

U.S. General Anesthesia Drugs Market

The U.S. market provides additional insights into the dynamics affecting Ultane.

Market Size and Growth

• The U.S. general anesthesia drugs market was valued at USD 1.92 billion in 2023 and is projected to grow to USD 2.56 billion by 2033, with a CAGR of 2.9% during the forecast period[1].

Segment Dominance

• The intravenous (IV) segment held the largest revenue share of 63.15% in 2023, but the inhalation segment, which includes Ultane, is also significant. The propofol segment dominated the market in 2023, but inhalation anesthetics are crucial in many surgical procedures[1].

Financial Trajectory of Ultane

To understand the financial trajectory of Ultane, we need to consider the performance of its parent market and the specific trends within the inhalation anesthetics segment.

Revenue Growth

• Given that the inhalation anesthetics market is growing at a CAGR of 4.57%, Ultane, as a key player in this segment, is likely to benefit from this growth. The increasing demand for inhalation anesthetics in surgical procedures, especially in knee and hip replacements and cancer treatments, will drive revenue growth[1][4].

Competitive Landscape

• Companies like Baxter, Lunan Pharmaceutical Group Co. Ltd, Piramal Enterprises Limited, Fresenius Kabi, and Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC) are major players in the inhalation anesthetics market. The competitive landscape will influence the pricing and market share of Ultane[4].

Impact of Healthcare Trends

Several healthcare trends are influencing the market dynamics of Ultane.

Increasing Surgical Procedures

• The rise in surgical procedures, particularly in segments like knee and hip replacements, is driving the demand for general anesthesia drugs, including inhalation anesthetics like Ultane[1].

Ambulatory Surgical Centers (ASCs)

• The growth of ASCs, which are anticipated to achieve the fastest CAGR of 3.6% during the forecast period, will also increase the demand for Ultane and other inhalation anesthetics[1].

Accessibility and Healthcare Services

• The gap in accessibility to healthcare services in low-income countries and distant locations affects the overall demand for anesthesia drugs. However, in regions with better healthcare infrastructure, the demand for Ultane is expected to remain strong[3].

Key Takeaways

• Market Growth: The global general anesthesia drugs market and the inhalation anesthetics segment are expected to grow steadily, driven by increasing demand in surgical procedures and advancements in healthcare infrastructure.
• Revenue Share: The intravenous segment dominates the U.S. general anesthesia drugs market, but the inhalation segment, including Ultane, holds significant revenue share and growth potential.
• Competitive Landscape: Major pharmaceutical companies are key players in the inhalation anesthetics market, influencing the market share and pricing of Ultane.
• Healthcare Trends: The rise in surgical procedures and the growth of ASCs are driving the demand for Ultane and other inhalation anesthetics.

FAQs

What is the projected growth rate of the global general anesthesia drugs market?

The global general anesthesia drugs market is expected to grow at a CAGR of 3.3% from 2023 to 2033[3].

How is the inhalation anesthetics market expected to grow?

The inhalation anesthetics market is expected to grow at a CAGR of 4.57% from 2024 to 2029, reaching USD 1.74 billion by 2029[4].

Which segment dominates the U.S. general anesthesia drugs market?

The intravenous (IV) segment held the largest revenue share of 63.15% in 2023, but the inhalation segment, including Ultane, is also significant[1].

What are the key drivers of the inhalation anesthetics market?

The application of inhalation anesthetics in COVID-19 treatment and the need for complex and high sedation in surgical procedures are key drivers of the market[4].

Which region is expected to grow the fastest in the inhalation anesthetics market?

The Asia Pacific region is expected to grow at the highest CAGR over the forecast period[4].

Sources

1. U.S. General Anesthesia Drugs Market Size to Hit USD 2.56 Billion by 2033 - Biospace
2. ULTA Stock Tumbles 27% in 6 Months: What's Next for Investors? - Nasdaq
3. General Anesthesia Drugs Market Size, Trends - 2033 - Future Market Insights
4. Inhalation Anesthesia Market - Trends, Growth, Share & Size - Mordor Intelligence
5. Ulta Beauty (NasdaqGS:ULTA) Stock Forecast & Analyst Predictions - Simply Wall St.